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injury (13 ). In patients with severe chronic heart failure
(NYHA III and NYHA IV), cTnI (4, 6) and cTnT (5, 7) are
often increased. In our study, none of three carriers with
an increased CK-MB/CK-total ratio had dilated cardio-
myopathy and none had detectable troponins. Thus a
CK-MB/CK-total ratio .3% did not appear to be indica-
tive of severe cardiac abnormalities in our study popula-
tion. Two carriers had detectable cTnT; in one carrier with
borderline echocardiographic abnormalities, it was
slightly increased. In all other carriers, cTnT was not
detectable. None of the carriers had detectable cTnI.
Although 30 women (23%) among the DMD/BMD carri-
ers showed left ventricle dilation or dilated cardiomyop-
athy on echocardiography, these abnormalities probably
reflected cardiac dysfunction rather than cardiac cell
necrosis. In our study group, no carrier had severe heart
failure that was associated with increased troponins. cTnI
and cTnT can be used, however, for carriers suspected of
cardiac ischemia. Measurement of CK-MB alone could
give a false-positive result because of high total CK.
Some authors have found a negative correlation be-
tween CK activity and age in DMD (14 ) and BMD carriers
(15 ), whereas others have not (16 ). We found no such
correlation, but we were able to demonstrate a linearly
decreasing trend of total CK with increasing age groups of
carriers. Surprisingly, only 53% of DMD carriers and 30%
of BMD carriers had increased total CK. Only one earlier
study found similar percentages (17 ), whereas most other
studies found raised CK activity in 60–80% in DMD
(16, 18–22) and 42–62% of BMD carriers (15, 20, 22).
These relatively high percentages prompted clinicians in
the predystrophin era to calculate the risk of being a
carrier. Perhaps the difference between our study and
those carried out before the 1990s is that in most of these
investigations, repeat measurements of total CK were
done, whereas we performed only one measurement.
In conclusion, detectable cTnI and cTnT are rare in
DMB and BMD carriers and bear no relationship with
disease-specific cardiac abnormalities. We cannot exclude
the possibility that cTnI and cTnT will be increased in
carriers with severe heart failure because no severe heart
failure was present in our study group.
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Relationship between Natriuretic Peptide Concentra-
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Measurements of the plasma concentrations of one or
more of the natriuretic peptides can be a valuable tool in
the diagnosis, prognosis, and follow-up of patients with
cardiac dysfunction (1, 2). Measurement techniques have
also improved, allowing for less time-consuming direct
assays than previous methods, which often required the
prior extraction of peptides from plasma. However, im-
provement is still needed (3 ).
In most research settings, blood sampling is performed
under carefully controlled conditions, involving the intro-
duction of a catheter and ample bed rest before the
collection of blood. Such procedures are necessary for the
reliable interpretation of many neurohormone measure-
ments. Catecholamines, for example, can fluctuate widely
depending on the blood-sampling procedure and posture.
Because strictly adhering to rigorous blood-sampling pro-
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tocols is often impossible in everyday clinical situations,
we investigated the variation in measured natriuretic
peptide concentrations because of differences in blood-
sampling conditions.
We have measured atrial natriuretic peptide (ANP),
brain natriuretic peptide (BNP), N-terminal-pro-ANP (Nt-
ANP), as well as the catecholamines noradrenaline
(NOR), adrenaline, renin (REN), and aldosterone (ALDO).
We studied subjects in the relevant age range (.40 years)
with diseases of interest in four different blood-sampling
conditions, while continuing appropriate medications for
these conditions. Twenty-three subjects (55 6 10 years;
range 42–74 years) participated in the study after giving
their informed consent. Six subjects were apparently
healthy controls (46 6 5 years; two females), nine were
hypertensive patients (53 6 7 years; two females), and
eight (64 6 9 years; three females) were patients with
diseases known to lead to increased concentrations of
natriuretic peptides: congestive heart failure (four sub-
jects) and chronic renal failure (four subjects). All patients
were taking appropriate medications for their conditions.
Immediately after entering the examination room in our
department, subjects sat down and a small catheter was
inserted into an antecubital vein. Blood was sampled
directly and then after 30 min of continued quiet sitting.
Blood was sampled again both after 30 min of lying on a
bed (bed rest) and after 30 min of standing and walking.
The whole procedure was repeated on a second visit, at
least 7 days later (median interval, 12 days) to assess
intraindividual variation from one day to another. The
procedure was always performed in the morning between
0900 and 1200.
Blood was collected in two different tubes: (a) one tube
containing EDTA and aprotinin (1.9 mg and 100 kIU/mL
of blood, respectively) for measurement of natriuretic
peptides and (b) one heparin-containing tube containing
1.2 mg of glutathione/mL of blood for measurement of
NOR, adrenaline, REN, and ALDO. The tubes were
centrifuged (3000g) within 30 min at 4 °C for 10 min, and
the plasma was separated and stored at 270 °C until
assayed. ANP was determined by RIAs (Nichols Institute)
after Sep-Pak C18 extraction from plasma. BNP was mea-
sured with immunoradiometric assays from Shionoria,
and Nt-ANP was measured with RIAs from Biotop, both
without extraction. Catecholamines were measured by
HPLC with fluorometric detection after extraction from
plasma and derivatization with dimedone (4 ). ALDO was
determined with RIAs from Diagnostic Products Corpo-
ration. REN was determined by RIA of generated angio-
tensin I (5 ). All methods used had intraassay CVs in the
relevant range of ,10%. All samples from one subject
were measured in the same assay.
Mean neurohormone concentrations of samples col-
lected after 30 min of bed rest on the first visit are reported
in Table 1, as are the concentrations for samples collected
directly after the subjects arrived and the samples col-
lected after 30 min of sitting and after 30 min of standing
and walking. The concentrations in Table 1 are also
expressed as percentages of the individual neurohormone
concentrations after 30 min of bed rest. ANOVA analysis
showed that the difference between the four procedures is
significant for all neurohormones, but posttests with
Bonferroni correction indicated that the differences in the
natriuretic peptides were small and often (with BNP) not
significant. In contrast to the well-known fact that REN
and ALDO vary quite considerably under different blood-
sampling conditions, natriuretic peptides appeared to be
much less variable. Samples collected directly after pa-
tients arrived gave somewhat higher values, but values
obtained during quiet sitting were indistinguishable from
those obtained during bed rest. For Nt-ANP, the differ-
ences were the smallest, which was not surprising in view
of its relatively long half-life. These findings agree with
the results of Wijbenga et al. (6 ), who, in a study on the
response of natriuretic peptides to exercise, found the
highest percentage of change in ANP, a smaller percent-
age of change in BNP, and the smallest percentage of
change in Nt-ANP. Nt-BNP, which was measured in that
study (6 ) but not in our present study, changed more than
Nt-ANP but less than BNP. For the catecholamines REN
and ALDO, there were considerable differences in the
values obtained directly after arrival and after 30 min of
bed rest, but the differences between the values obtained
after 30 min of sitting and after 30 min of bed rest were
much smaller. Furthermore, Bonferroni posttests pro-
duced statistically significant results for ALDO only. The
lack of statistical significance for the difference between
sitting and bed rest values for NOR and adrenaline














AngI z L21 z h21
Basal values (after 30 min of bed rest)
Mean 6 SD 52 6 28 6.1 6 7.2 448 6 292 273 6 127 30 6 26 91 6 48 19.0 6 31.5
Range 26–122 0.7–27.0 72–1152 114–700 6–116 19–185 2.2–112.6
% of basal (mean 6 SD) when sampled
Direct sampling 124 6 49b 114 6 23 108 6 15b 186 6 59b 190 6 99b 162 6 55b 126 6 30b
After 30 min of sitting 99 6 20 101 6 17 104 6 12 127 6 33 122 6 37 128 6 31b 112 6 18
After 30 min of standing/walking 114 6 29 116 6 36 110 6 16b 228 6 95b 155 6 54b 159 6 90b 129 6 42b
ANOVA P value 0.0046 0.0188 0.0066 ,0.0001 ,0.0001 ,0.0001 ,0.0001
a ADR, adrenaline; AngI, angiotensin I.
b Significantly different from basal.
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contrasts with previous findings from our laboratory (7 ).
In that study, however, only young healthy subjects took
part, whereas in the present study, subjects were older,
and most had diseases associated with an activation of the
sympathetic nervous system. We should mention that in
younger subjects, some neurohormones may have a
greater response than in the group of older subjects we
studied. The effects of medication used by all patients
may have also played a role.
At the second visit (again as a percentage relative to the
samples collected at the first visit after 30 min of bed rest),
the pattern was much the same as at the first visit. The
difference between the four procedures was significant
for all neurohormones, and posttests broadly showed
similar results as on the first visit. Correlations between
absolute values for the same blood-sampling procedure at
the first visit vs those at the second visit were all signifi-
cant, except for NOR after 30 min of standing and
walking. A good impression of individual differences
could be obtained by constructing Bland–Altman plots
(8 ), which are shown for the natriuretic peptides in the
sitting situation in Fig. 1. These indicate that although
usually there was good agreement between measure-
ments on the two different visits, occasionally a large
difference was found. This could be a result of the timing
of the medication used (e.g., the effects of angiotensin-
converting enzyme inhibitors on REN and ALDO values),
but sometimes also for no apparent reason. Here again,
the differences in Nt-ANP and BNP appeared to be the
smallest.
Which of the various natriuretic peptides is (are) most
informative with regard to the diagnosis, course, and
treatment of heart failure is still being debated. From the
viewpoint of stability in blood samples, the N-terminal
peptides, as well as BNP, appear to be the best (9–13).
ANP is less stable, although not as unstable as has been
suggested (14 ). In addition, because of longer half-lives,
short-term fluctuations will have less of an effect on the
measured concentrations of the N-terminal peptides than
of the C-terminal peptides. However, clinical studies are
needed to determine which is (are) the most informative.
We conclude that the measurement of natriuretic pep-
tides in a single blood sample, obtained after 30 min of
quiet sitting, can give reliable and reproducible basal
values. Measurements of the catecholamines REN and
ALDO in the same blood sample are only marginally
higher than values obtained after 30 min of bed rest.
Especially for BNP and Nt-ANP, blood sampling directly
after arrival may be a reasonable alternative when time
and/or facilities are limited.
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Fig. 1. Bland–Altman plots of absolute differences in ANP, BNP, and Nt-ANP between the two visits (blood sampling after 30 min sitting).
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